Drug Innovation Archives - Page 6 of 10 - Pacific Research Institute

Drug Innovation

Commentary

Simple Fix for Healthcare: Give Patients More Responsibility

Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
Drug Innovation

NEW BRIEF: Promoting Transparency and Competition in the Drug Market

DOWNLOAD THE BRIEF   BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include:   fostering a ...
Commentary

The Inflation Reduction Act Kills the Golden Goose That Could End Cancer

President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest.   The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Commentary

Pay No Attention To Biden’s Biotech Bluster

Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.”   His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
Commentary

The FDA Is Blocking Game-Changing New Drugs For Kidney Disease

Imagine you’ve been diagnosed with chronic kidney disease, told by your physician that if it can’t be managed, you may eventually need a transplant or long-term dialysis. This scary situation is one faced by hundreds of thousands of Americans every year. Chronic kidney disease (CKD) is an illness that affects an ...
Commentary

Drug Importation Doesn’t Save Money — It Costs Lives

Proponents of prescription-drug importation notched a victory last week. The Senate Health, Education, Labor, and Pensions Committee green-lit a bill that would enable individuals to import medicines from Canada in the name of lowering out-of-pocket costs. It’s not something Americans should welcome or support. Drugs imported from outside the United States will ...
Commentary

Promote Regulatory Certainty By Reauthorizing UFA

The House passed bipartisan legislation last week that could help reduce costs and ensure continued innovation for the future. While this legislation might not be covered as extensively as other issues, it nonetheless represents meaningful progress. This week, the Senate HELP Committee passed the Senate version, the Food and Drug ...
Commentary

Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Just a few days ago, it appeared that Democrats had given up on including prescription drug pricing reforms in their massive spending bill. But not anymore. In an eleventh-hour turn of events, congressional Democrats this week resurrected their long-standing desire to levy government price controls on prescription drugs. If lawmakers successfully deploy their latest ...
Commentary

Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever

One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to ...
Commentary

Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives

President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system ...
Commentary

Simple Fix for Healthcare: Give Patients More Responsibility

Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
Drug Innovation

NEW BRIEF: Promoting Transparency and Competition in the Drug Market

DOWNLOAD THE BRIEF   BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include:   fostering a ...
Commentary

The Inflation Reduction Act Kills the Golden Goose That Could End Cancer

President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest.   The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Commentary

Pay No Attention To Biden’s Biotech Bluster

Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.”   His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
Commentary

The FDA Is Blocking Game-Changing New Drugs For Kidney Disease

Imagine you’ve been diagnosed with chronic kidney disease, told by your physician that if it can’t be managed, you may eventually need a transplant or long-term dialysis. This scary situation is one faced by hundreds of thousands of Americans every year. Chronic kidney disease (CKD) is an illness that affects an ...
Commentary

Drug Importation Doesn’t Save Money — It Costs Lives

Proponents of prescription-drug importation notched a victory last week. The Senate Health, Education, Labor, and Pensions Committee green-lit a bill that would enable individuals to import medicines from Canada in the name of lowering out-of-pocket costs. It’s not something Americans should welcome or support. Drugs imported from outside the United States will ...
Commentary

Promote Regulatory Certainty By Reauthorizing UFA

The House passed bipartisan legislation last week that could help reduce costs and ensure continued innovation for the future. While this legislation might not be covered as extensively as other issues, it nonetheless represents meaningful progress. This week, the Senate HELP Committee passed the Senate version, the Food and Drug ...
Commentary

Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Just a few days ago, it appeared that Democrats had given up on including prescription drug pricing reforms in their massive spending bill. But not anymore. In an eleventh-hour turn of events, congressional Democrats this week resurrected their long-standing desire to levy government price controls on prescription drugs. If lawmakers successfully deploy their latest ...
Commentary

Democrats $3.5 Trillion Budget Leaves the Health Care Sector as Broken as Ever

One of the most striking aspects of the $3.5 trillion budget resolution proposed last week by Senate Democrats is how little it does to improve America’s ailing healthcare system. The plan funnels massive sums of money into everything from Medicare and Medicaid to Obamacare’s premium tax credits. But it utterly fails to ...
Commentary

Biden’s Intellectual Property Waiver Puts Political Symbolism Before Saving Lives

President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system ...
Scroll to Top